Amneal (NYSE:AMRX) is building one of the most dynamic pharmaceutical companies in our industry. Today’s healthcare environment requires new ideas. While staying true to our reputation for quality, service and value in pharmaceuticals, we are challenging ourselves, our playbook and the status quo. We are uniting people, passion and products to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow’s health challenges. We are Amneal and “We make healthy possible.” Learn more about how we’re making a difference in generics, brands and biosimilars at Amneal.com.
Location: United States, New Jersey
Employees: 5001-10000
Founded date: 2002
Investors 1
| Date | Name | Website |
| - | Tarsadia I... | tarsadia.c... |
Mentions in press and media 5
| Date | Title | Description |
| 03.05.2024 | Attorney General Bonta Announces $273 Million Nationwide Agreement with Amneal Pharmaceuticals for its Role in the Opioid Epidemic | OAKLAND — California Attorney General Rob Bonta today announced a nationwide agreement in principle on monetary terms that will require opioid manufacturer Amneal Pharmaceuticals to pay up to $272.5 million nationally to address its role in... |
| 29.03.2024 | Health | Experts say Medicaid rebate change is behind inhaler price cuts | Lauren Clason | (TNS) CQ-Roll Call A recent tweak to a Medicaid formula could be behind the shake-up to inhaler products, a series of changes that have both benefited and harmed patients with asthma and chronic obstructive pulmonary disease... |
| 26.02.2021 | Amneal Reports Fourth Quarter and Full Year 2020 Financial Results | BRIDGEWATER, N.J.--(BUSINESS WIRE)--Feb 26, 2021-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and full year ended December 31, 2020. "We are extremely proud of... |
| 26.02.2021 | Amneal Receives Approval for Generic Version of Ortho Evra® | BRIDGEWATER, N.J.--(BUSINESS WIRE)--Feb 26, 2021-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Admin... |
| 14.11.2016 | Term Sheet — Monday, November 14 | ET CETERA Hello from the home office, where any non-Trump news seems beside the point. A few brief notes to kick off your Monday: Paid Content Securing the enterprise without boundaries From ExtraHop At Y Combinator, where Thiel is a part-t... |